A phase 1b, multi-center, open-label trial of evaluating pharmacokinetic profile of RA101495 in patients with renal impairment

Trial Profile

A phase 1b, multi-center, open-label trial of evaluating pharmacokinetic profile of RA101495 in patients with renal impairment

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs RA 101495 (Primary)
  • Indications Haemolytic uraemic syndrome; Lupus nephritis
  • Focus Pharmacokinetics
  • Sponsors Ra Pharmaceuticals
  • Most Recent Events

    • 08 Jan 2018 According to a Ra Pharmaceuticals media release, the company has initiated dosing subjects with renal impairment in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top